Sugi Predict

Sugi Predict / Compounds / SCHEMBL1315380

SCHEMBL1315380

SCHEMBL1315380

CCCCCCCCCC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.73
▸ ESR1 P03372 6/20 0.73
▸ SMN1; SMN2 Q16637 5/20 0.73
▸ ADORA3 P0DMS8 3/20 0.73
▸ ATM Q13315 3/20 0.73
▸ PGR P06401 3/20 0.73
▸ AR P10275 3/20 0.73
▸ CHRM1 P11229 2/20 0.73
▸ TBXA2R P21731 2/20 0.73
▸ SLC6A3 Q01959 2/20 0.73
▸ ADRA1A P35348 1/20 0.73
▸ OPRM1 P35372 1/20 0.73
▸ KMT2A Q03164 5/20 0.67
▸ NR3C1 P04150 2/20 0.67
▸ SHBG P04278 2/20 0.67
▸ SLC6A4 P31645 2/20 0.67
▸ HTR2B P41595 2/20 0.67
▸ FYN P06241 1/20 0.67
▸ ADRA2C P18825 1/20 0.67
▸ SLC6A2 P23975 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17419466 1.00 LMNA (0.73) LMNAESR1SMN1; SMN2ADORA3ATM
SCHEMBL547938 1.00 LMNA (0.73) LMNAESR1SMN1; SMN2ADORA3ATM
SCHEMBL17419453 1.00 LMNA (0.73) LMNAESR1SMN1; SMN2ADORA3ATM
SCHEMBL548012 1.00 LMNA (0.73) LMNAESR1SMN1; SMN2ADORA3ATM
Estradiol Acetate SCHEMBL547226 0.97 LMNA (0.80) LMNAESR1SMN1; SMN2ADORA3ATM
SCHEMBL4333126 0.96 LMNA (0.75) LMNAESR1SMN1; SMN2ADORA3ATM
SCHEMBL40564 0.96 LMNA (0.75) LMNAESR1SMN1; SMN2ADORA3ATM
SCHEMBL11102416 0.96 LMNA (0.75) LMNAESR1SMN1; SMN2ADORA3ATM
SCHEMBL9404736 0.94 LMNA (0.77) LMNAESR1SMN1; SMN2ADORA3ATM
SCHEMBL7633202 0.93 LMNA (0.73) LMNAESR1SMN1; SMN2ADORA3ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111032024-A Bioerodible drug delivery implant 赫拉健康解决方案公司 2020-04-17 — — CN claimed
US-20080279915-A1 Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen HEXAL AG (DE) 2008-11-13 — — US claimed
US-20070155673-A1 USE OF BVDU FOR INHIBITING THE GROWTH OF HYPERPROLIFERATIVE CELLS CELMED ONCOLOGY (USA), INC. 2007-07-05 — — US claimed
US-20050080035-A1 Use of BVDU for inhibiting the growth of hyperproliferative cells CELMED ONCOLOGY (USA), INC. (CA) 2005-04-14 — — US claimed
US-20030212037-A1 Use of bvdu for inhibiting the growth of hyperproliferative cells OPSEC SECURITY GROUP, INC. 2003-11-13 — — US claimed
WO-2003068186-A1 PHARMACEUTICAL FORMULATIONS AND SYSTEMS FOR IMPROVED ABSORPTION AND MULTISTAGE RELEASE OF ACTIVE AGENTS LIPOCINE, INC. (US) 2003-08-21 — — WO claimed
EP-1251836-A2 USE OF BVDU FOR INHIBITING THE GROWTH OF HYPERPROLIFERATIVE CELLS NewBiotics, Inc. (US) 2002-10-30 — — EP claimed
WO-2001045690-A2 USE OF BVDU FOR INHIBITING THE GROWTH OF HYPERPROLIFERATIVE CELLS NEWBIOTICS, INC. (US) 2001-06-28 — — WO claimed
US-6149935-A INCORPORATING AN ESTROGEN INTO PRESSURE SENSITIVE ADHESIVE MATERIAL AND VOLATILE SOLVENT TO FORM HOMOGENEOUS SOLUTION OR SLURRY; CASTING HOMOGENEOUS SOLUTION OR SLURRY; EVAPORATING VOLATILE SOLVENT TO FORM SOLID MATRIX ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-11-21 — — US claimed
US-5980932-A A PRESSURE SENSITIVE ADHESIVE MATRIX COMPRISING AT LEAST ONE ESTROGEN DISPERSED IN THE BODY, FREE OF A SKIN PERMEATION ENHANCER; SIDE EFFECT REDUCTION, SOLVENT-FREE, LESS IRRITATION CYGNUS, INC. (US) 1999-11-09 — — US claimed
US-5906830-A POLYMER, DRUG MIXTURE CYGNUS, INC. (US) 1999-05-25 — — US claimed
US-5902603-A INCLUDING A PERMEABILITY ENHANCER ABSORBED THEREIN; HIGHER LOADS; HIGH CAPACITY AND FLUX; CROSSLINKED POLYURETHANE REACTED WITH WATER; ADMINISTERING STEROIDS AND OLANZAPINE CYGNUS, INC. (US) 1999-05-11 — — US claimed
US-5770219-A Solid matrix system for transdermal drug delivery CYGNUS INC. (US) 1998-06-23 — — US claimed
US-5116865-A Antifertility Agents SRI INTERNATIONAL, A CORP OF CA 1992-05-26 — — US claimed
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF VAN BOGAERT GINA (BE) 2026-01-15 — — US disclosed
CN-119157859-A Bioerodible drug delivery implant 赫拉健康解决方案公司 2024-12-20 — — CN disclosed
WO-2023223235-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF PURNA PHARMACEUTICALS NV (BE) 2023-11-23 — — WO disclosed
WO-1998039012-A1 USE OF A 7α-METHYL-17α-ETHYNYL-ESTRANE DERIVATIVE FOR THE TREATMENT OF ATHEROSCLEROSIS AKZO NOBEL N.V. (NL) 1998-09-11 — — WO disclosed
US-5091188-A PHOSPHOLIPID-COATED MICROCRYSTALS: INJECTABLE FORMULATIONS OF WATER-INSOLUBLE DRUGS RTP PHARMA CORPORATION 1992-02-25 — — US disclosed
US-5091187-A Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs SKYEPHARMA AG (CH) 1992-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF NR5A1, SHBG, GNRHR LMNA 796/4885ESR1 188/4885SMN1; SMN2 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.